Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guofan Xu

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|April 3, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|April 3, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, et al.
Pageof 7